Cloth masks are not as effective at curbing the spread of COVID-19 as surgical masks; Martin Shkreli is banned from the pharmaceutical industry; as infections increase, more COVID-19 variants are likely.
In an update to its masking recommendations, the CDC conceded that cloth masks do not offer as much protection from COVID-19 compared with surgical masks or N95 respirators, The New York Times reports. However, the agency did not go so far as to recommend respirators for ordinary citizens and stated the more protective masks can be considered in situations where greater protection is needed or desired. When used correctly, N95 masks can filter out 95% of all airborne particles.
A federal judge ruled Martin Shkreli must return the $64 million in profits he made by hiking up the price of the life-saving drug Daraprim and monopolizing the market, according to the Associated Press. Shkreli, the former CEO of Vyera Pharmaceuticals LLC, has also been barred from the pharmaceutical industry for life. In 2015, Shkreli’s company raised the price of Daraprim from $13.50 to $750 per pill. The treatment is used for a rare parasitic disease that can affect pregnant women and patients with AIDS.
Scientists are warning that Omicron won’t be the last variant of COVID-19 to worry the world, as every infection is a new chance for the virus to mutate, the Associated Press reports. As it’s unknown what future variants may look like, experts cautioned there is no guarantee that they will be more mild than Omicron or that existing vaccines will be effective against them. Increasing vaccination rates now, while the shots are still effective, can help reduce the overall number of infections and reduce the virus’ chance of mutation.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More